Rick Bienkowski
Stock Analyst at Cantor Fitzgerald
(0.35)
# 4,009
Out of 4,711 analysts
34
Total ratings
17.86%
Success rate
-29.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Rick Bienkowski
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Reiterates: Overweight | $83 | $34.08 | +143.54% | 2 | Dec 9, 2024 | |
| BEAM Beam Therapeutics | Upgrades: Outperform | $27 → $39 | $29.01 | +34.44% | 10 | Nov 6, 2024 | |
| ACLX Arcellx | Initiates: Overweight | n/a | $75.54 | - | 1 | Sep 3, 2024 | |
| NTLA Intellia Therapeutics | Reiterates: Overweight | $65 | $12.18 | +433.66% | 7 | Jun 24, 2024 | |
| CRBU Caribou Biosciences | Initiates: Neutral | n/a | $1.80 | - | 1 | Nov 8, 2023 | |
| VERV Verve Therapeutics | Reiterates: Neutral | $22 | $5.74 | +283.28% | 3 | Sep 13, 2023 | |
| EDIT Editas Medicine | Reiterates: Overweight | $14 | $1.31 | +968.70% | 6 | Sep 13, 2023 | |
| CRSP CRISPR Therapeutics AG | Maintains: Outperform | $112 → $107 | $40.72 | +162.77% | 4 | Aug 8, 2022 |
Legend Biotech
Dec 9, 2024
Reiterates: Overweight
Price Target: $83
Current: $34.08
Upside: +143.54%
Beam Therapeutics
Nov 6, 2024
Upgrades: Outperform
Price Target: $27 → $39
Current: $29.01
Upside: +34.44%
Arcellx
Sep 3, 2024
Initiates: Overweight
Price Target: n/a
Current: $75.54
Upside: -
Intellia Therapeutics
Jun 24, 2024
Reiterates: Overweight
Price Target: $65
Current: $12.18
Upside: +433.66%
Caribou Biosciences
Nov 8, 2023
Initiates: Neutral
Price Target: n/a
Current: $1.80
Upside: -
Verve Therapeutics
Sep 13, 2023
Reiterates: Neutral
Price Target: $22
Current: $5.74
Upside: +283.28%
Editas Medicine
Sep 13, 2023
Reiterates: Overweight
Price Target: $14
Current: $1.31
Upside: +968.70%
CRISPR Therapeutics AG
Aug 8, 2022
Maintains: Outperform
Price Target: $112 → $107
Current: $40.72
Upside: +162.77%